🔗 Share this article

As America undertakes sweeping revisions to its vaccine schedules, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning Covid vaccinations in the pandemic and has zeroed in on possible fatalities after Covid immunization in her recent tenure at the FDA.

Planned Overhauls to Childhood Immunization Program

Health officials had intended to announce major changes to the childhood vaccine schedule recently, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with little proof for benefit. This reveal has been postponed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A Shift at the Agency

This interim role might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for halting certain pediatric shot schedules in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a population roughly the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Dr. Høeg has little discernible background in drug development, oversight or administrative roles, which has been typical for previous leaders of the CBER. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Past directors of CBER would “grasp laws and regulations and the science of drug development”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who led CBER have had.”

CDER has an vast workload at the agency, she emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and each of these must be looked after,” she explained. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative element to the position, which supervises in excess of 5,000 personnel. “It is a huge administrative position, if you do it right,” she added.

Response and Contentious Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this appointment indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “concerns rely on inaccurate presumptions”.

“Her resume aligns with the functions of her role,” the official stated, noting the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's recently launched expedited review system, a contentious rapid therapy clearance system that apparently troubled her predecessors. “By what process are these therapies being chosen for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the agency appears to be shifting towards laxer oversight of most medications, aside from immunizations.”

Documented Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, critics said. She released a study using unconfirmed crowd-sourced reports to determine the frequency of myocarditis after COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the new administration included altering regulations for recently developed shots and ending “unnecessary” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has reportedly suggested preventing teenage boys from getting COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her conclusions and tailors the evidence to fit the science in a highly deceptive, untruthful manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|